{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:02:44Z","timestamp":1780326164118,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41434-026-00596-3","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:03:39Z","timestamp":1773399819000},"page":"310-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Building a gene editing lexicon: a model for rare and inherited disorders"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6418","authenticated-orcid":false,"given":"Leonard A.","family":"Valentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Unzu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheala","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gutstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1916-041X","authenticated-orcid":false,"given":"William","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"596_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102696","volume":"9","author":"LA Valentino","year":"2025","unstructured":"Valentino LA, Santaella ME, Carlson SA, Recht M. Contemporary approaches to treat people with hemophilia: what\u2019s new and what\u2019s not? Res Pract Thromb Haemost. 2025;9:102696.","journal-title":"Res Pract Thromb Haemost"},{"key":"596_CR2","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1111\/hae.13504","volume":"24","author":"A Iorio","year":"2018","unstructured":"Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, et al. Core outcome set for gene therapy in haemophilia: results of the coreHEM multistakeholder project. Haemophilia. 2018;24:e167\u201372.","journal-title":"Haemophilia"},{"key":"596_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41687-023-00550-6","volume":"7","author":"M Brod","year":"2023","unstructured":"Brod M, Bushnell DM, Neergaard JS, Waldman LT, Busk AK. Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM). J Patient Rep Outcomes. 2023;7:17.","journal-title":"J Patient Rep Outcomes"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/hae.13769","volume":"25","author":"W Miesbach","year":"2019","unstructured":"Miesbach W, O\u2019Mahony B, Key NS, Makris M. How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia. 2019;25:545\u201357.","journal-title":"Haemophilia"},{"key":"596_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjh.14297","volume":"175","author":"H Zhang","year":"2016","unstructured":"Zhang H, McCarty N. CRISPR-Cas9 technology and its application in haematological disorders. Br J Haematol. 2016;175:208\u201325.","journal-title":"Br J Haematol"},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1089\/hum.2023.112","volume":"34","author":"D De Wolf","year":"2023","unstructured":"De Wolf D, Singh K, Chuah MK, VandenDriessche T. Hemophilia gene therapy: the end of the beginning? Hum Gene Ther. 2023;34:782\u201392.","journal-title":"Hum Gene Ther"},{"key":"596_CR7","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.ymthe.2025.04.023","volume":"33","author":"CD Thornburg","year":"2025","unstructured":"Thornburg CD, Pipe SW, Cantore A, Unzu C, Jones M, Miesbach WA. Clinical perspective: advancing hemophilia treatment through gene therapy approaches. Mol Ther. 2025;33:2350\u201362.","journal-title":"Mol Ther"},{"key":"596_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","volume":"9","author":"XP Duan","year":"2024","unstructured":"Duan XP, Qin BD, Jiao XD, Liu K, Wang Z, Zang YS. New clinical trial design in precision medicine: discovery, development and direction. Signal Transduct Target Ther. 2024;9:57.","journal-title":"Signal Transduct Target Ther"},{"key":"596_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","volume":"403","author":"A Schambach","year":"2024","unstructured":"Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, et al. A new age of precision gene therapy. Lancet. 2024;403:568\u201382.","journal-title":"Lancet"},{"key":"596_CR10","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/hae.15108","volume":"30","author":"C Hermans","year":"2024","unstructured":"Hermans C, Valentino LA, Thornburg CD, Unzu C, Kay MA, Peyvandi F, et al. A novel gene editing lexicon strategy for the haemophilia community: research plan for development and preliminary results. Haemophilia. 2024;30:1272\u201380.","journal-title":"Haemophilia"},{"key":"596_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14291","volume":"54","author":"F Dennst\u00e4dt","year":"2024","unstructured":"Dennst\u00e4dt F, Putora PM, Iseli T, Treffers T, Panje C, Fischer GF. Patient autonomy and shared decision-making in the context of clinical trial participation. Eur J Clin Invest. 2024;54:e14291.","journal-title":"Eur J Clin Invest"},{"key":"596_CR12","unstructured":"NIST. NIST genome editing lexicon. 2024. https:\/\/www.nist.gov\/programs-projects\/nist-genome-editing-lexicon. Accessed May 28, 2025."},{"key":"596_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/17474086.2023.2178410","volume":"16","author":"E V\u00e1zquez","year":"2023","unstructured":"V\u00e1zquez E, Kim M, Santaella ME. Lived experience experts: a name created by us for us. Expert Rev Hematol. 2023;16:7\u201311.","journal-title":"Expert Rev Hematol"},{"key":"596_CR14","first-page":"e234","volume":"5","author":"D Schillinger","year":"2021","unstructured":"Schillinger D. Social determinants, health literacy, and disparities: intersections and controversies. Health Lit Res Pract. 2021;5:e234\u201343.","journal-title":"Health Lit Res Pract"},{"key":"596_CR15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13187-022-02202-7","volume":"38","author":"M Kopec","year":"2023","unstructured":"Kopec M, Quartey NK, Snow M, Stechkevich A, Giuliani ME, Papadakos J. Improving access to patient education: an audit of extant educational materials. J Cancer Educ. 2023;38:885\u201394.","journal-title":"J Cancer Educ"},{"key":"596_CR16","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014.","journal-title":"Gastroenterology"},{"key":"596_CR17","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"596_CR18","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14478","volume":"40","author":"Y Fouad","year":"2020","unstructured":"Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What\u2019s in a name? Renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019. Liver Int. 2020;40:1254\u201361.","journal-title":"Liver Int"},{"key":"596_CR19","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29:S17\u201331.","journal-title":"Clin Mol Hepatol"},{"key":"596_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/17474086.2024.2353761","volume":"17","author":"CD Thornburg","year":"2024","unstructured":"Thornburg CD, Coffin D. How clinicians and persons with hemophilia may approach shared decision-making. Expert Rev Hematol. 2024;17:193\u20136.","journal-title":"Expert Rev Hematol"},{"key":"596_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.pec.2018.01.006","volume":"101","author":"U Stenberg","year":"2018","unstructured":"Stenberg U, V\u00e5gan A, Flink M, Lynggaard V, Fredriksen K, Westermann KF, et al. Health economic evaluations of patient education interventions a scoping review of the literature. Patient Educ Couns. 2018;101:1006\u201335.","journal-title":"Patient Educ Couns"},{"key":"596_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102710","volume":"9","author":"CM Kessler","year":"2025","unstructured":"Kessler CM, Valentino LA, Thornburg CD, Unzu C, Kay MA, Peyvandi F, et al. Development of a novel gene editing lexicon for hemophilia: methodology and results. Res Pract Thromb Haemost. 2025;9:102710.","journal-title":"Res Pract Thromb Haemost"},{"key":"596_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/hae.15155","volume":"31","author":"W McKeown","year":"2022","unstructured":"McKeown W, Hermans C, Unzu C, Kay MA, Peyvandi F, Smith P, et al. Operationalising a haemophilia gene editing lexicon for practical use. Haemophilia. 2022;31:207\u201313.","journal-title":"Haemophilia"},{"key":"596_CR24","unstructured":"World Federation of Hemophilia. Gene therapy. 2022. https:\/\/elearning.wfh.org\/elearning-centres\/gene-therapy\/. Accessed May 28, 2025."},{"key":"596_CR25","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0277-9536(96)00221-3","volume":"44","author":"C Charles","year":"1997","unstructured":"Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997;44:681\u201392.","journal-title":"Soc Sci Med"},{"key":"596_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, Mahn M, et al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31:616\u201330.","journal-title":"Mol Ther"},{"key":"596_CR27","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","volume":"30","author":"M Muhuri","year":"2022","unstructured":"Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Ther. 2022;30:1364\u201380.","journal-title":"Mol Ther"},{"key":"596_CR28","unstructured":"Care Learning. What is informed consent in health and social care? 2024. https:\/\/carelearning.org.uk\/blog\/consent\/what-is-informed-consent-in-health-and-social-care\/. Accessed May 28, 2025."},{"key":"596_CR29","unstructured":"World Health Organization. Achieving well-being: a global framework for integrating well-being into public health utilizing a health promotion approach. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240084858. Accessed May 28, 2025."},{"key":"596_CR30","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.pec.2006.06.018","volume":"63","author":"C Charles","year":"2006","unstructured":"Charles C, Gafni A, Whelan T, O\u2019Brien MA. Cultural influences on the physician-patient encounter: the case of shared treatment decision-making. Patient Educ Couns. 2006;63:262\u20137.","journal-title":"Patient Educ Couns"},{"key":"596_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11606-020-05912-0","volume":"36","author":"DM Muscat","year":"2021","unstructured":"Muscat DM, Shepherd HL, Nutbeam D, Trevena L, McCaffery KJ. Health literacy and shared decision-making: exploring the relationship to enable meaningful patient engagement in healthcare. J Gen Intern Med. 2021;36:521\u20134.","journal-title":"J Gen Intern Med"},{"key":"596_CR32","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","volume":"31","author":"Y Fu","year":"2013","unstructured":"Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31:822\u20136.","journal-title":"Nat Biotechnol"},{"key":"596_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25:249\u201354.","journal-title":"Nat Med"},{"key":"596_CR34","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1056\/NEJMsa021212","volume":"348","author":"MK Paasche-Orlow","year":"2003","unstructured":"Paasche-Orlow MK, Taylor HA, Brancati FL. Readability standards for informed-consent forms as compared with actual readability. N Engl J Med. 2003;348:721\u20136.","journal-title":"N Engl J Med"},{"key":"596_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156\u201364.","journal-title":"Contemp Clin Trials Commun"},{"key":"596_CR36","unstructured":"American Society of Gene & Cell Therapy. Gene, cell, & RNA therapy landscape report. 2024. https:\/\/www.asgct.org\/publications\/landscape-report. Accessed May 28, 2025."},{"key":"596_CR37","unstructured":"bluebird bio. Welcome to genehome. 2021. https:\/\/www.thegenehome.com\/. Accessed May 28, 2025."},{"key":"596_CR38","unstructured":"Thalassaemia International Federation. Thalassaemia from \u2018A\u2019 to \u2018Z\u2019: a comprehensive e-glossary for patients with thalassaemia (2019). 2019. https:\/\/thalassaemia.org.cy\/publications\/tif-publications\/thalassaemia-from-a-to-z-a-comprehensive-e-glossary-for-patients-with-thalassaemia\/. Accessed May 28, 2025."},{"key":"596_CR39","unstructured":"Thalassaemia International Federation. Gene therapy in \u03b2-thalassaemia and other haemoglobin disorders (2019). 2019. https:\/\/thalassaemia.org.cy\/publications\/tif-publications\/gene-therapy-in-%ce%b2-thalassaemia-and-other-haemoglobin-disorders-2019\/. Accessed May 28, 2025."},{"key":"596_CR40","unstructured":"Vertex Pharmaceuticals. How does the CRISPR\/Cas system work? 2023. https:\/\/www.genepossibilities.com\/crispr-cas-system. Accessed May 28, 2025."},{"key":"596_CR41","unstructured":"Vertex Pharmaceuticals. Gene therapy information for HCPs. 2023. https:\/\/www.genepossibilitieshcp.com\/. Accessed May 28, 2025."},{"key":"596_CR42","unstructured":"Pagliarulo N, Gwendolyn W. Gene therapy uptake in sickle cell stays slow, despite patient interest. BioPharma Dive. 2024. https:\/\/www.biopharmadive.com\/news\/sickle-cell-gene-therapy-slow-uptake-casgevy-lyfgenia\/734938\/. Accessed May 28, 2025."},{"key":"596_CR43","unstructured":"Intellia Therapeutics. Glossary. 2025. https:\/\/www.intelliatx.com\/our-science\/glossary\/. Accessed May 28, 2025."},{"key":"596_CR44","unstructured":"G\u00e9n\u00e9thon. Understanding gene therapy. https:\/\/www.genethon.com\/our-science\/the-future-of-gene-therapy\/understanding-gene-therapy\/. Accessed May 28, 2025."},{"key":"596_CR45","unstructured":"Ultragenyx. Understanding gene therapy. 2024. https:\/\/www.ultrarareadvocacy.com\/understanding-drug-development\/understanding-gene-therapy\/. Accessed May 28, 2025."},{"key":"596_CR46","unstructured":"Verve Therapeutics. Patients & caregivers. 2025. https:\/\/www.vervetx.com\/patients-caregivers. Accessed May 28, 2025."},{"key":"596_CR47","unstructured":"uniQure. Community resources. 2024. https:\/\/www.uniqure.com\/patients-families\/community-resources. Accessed May 28, 2025."},{"key":"596_CR48","unstructured":"Cystic Fibrosis Foundation. Gene therapy for cystic fibrosis. https:\/\/www.cff.org\/research-clinical-trials\/gene-therapy-cystic-fibrosis. Accessed May 28, 2025."},{"key":"596_CR49","unstructured":"American Society of Gene & Cell Therapy. Gene & cell therapy education. 2025. https:\/\/patienteducation.asgct.org\/. Accessed May 28, 2025."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00596-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00596-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00596-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:05:42Z","timestamp":1780322742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00596-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00596-3","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LAV: received consulting fees from Takeda Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Inovio Pharmaceuticals, Inc., and HEMA Biologics, Inc. CH: received consulting fees from BioMarin Pharmaceutical, CSL Behring, LFB Biopharmaceuticals, Novo Nordisk, Octapharma, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi, and Sobi; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events for BioMarin Pharmaceutical, CSL Behring, LFB Biopharmaceuticals, Novo Nordisk, Octapharma, Pfizer, Sanofi, and Sobi; received support for attending meetings and\/or travel from LFB Biopharmaceuticals and Sobi; and participated in a data safety monitoring board or advisory board for CSL Behring. DC: full-time employee of the World Federation of Hemophilia and has received payment as an advisor from BioMarin Pharmaceutical and Regeneron Pharmaceuticals, Inc. WM: Bayer, BioMarin Pharmaceutical, Biotest, CSL Behring, Chugai, Freeline, LFB Biopharmaceuticals, Novo Nordisk, Octapharma, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, Sanofi, Sobi, Takeda\/Shire, uniQure. MEM: acted as a paid consultant, speaker, and\/or advisor for Bayer, BioMarin, CSL Behring, Kedrion, LFB Biopharmaceuticals, Novo Nordisk, Octapharma, Pfizer, Sanofi, Sobi, Roche, Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceuticals, Inc. CU: received a grant from Pfizer Global Medical Grants competitive grant program; and consulting fees from Regeneron Pharmaceuticals, Inc. MJ: employee of, and holds stock or stock options for, Regeneron Pharmaceuticals, Inc. DEG: employee of, and holds stock or stock options for, Regeneron Pharmaceuticals, Inc. WMc: received honoraria from Regeneron Pharmaceuticals, Inc.; and payment for expert testimony from BioMarin Pharmaceutical, CSL Behring, and Sobi. CMK: received grants\/research support from Bayer, Genentech, Octapharma, and Regeneron Pharmaceuticals, Inc.; consulting fees from Bayer, Biogen, BioMarin Pharmaceutical, CSL Behring, Genentech, Novo Nordisk, Octapharma, Pfizer, and Takeda Pharmaceuticals, Inc.; and participated in a data safety monitoring board for Bayer and Octapharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval and informed consent were not needed, as no human or animal experiments were conducted and no identifiable data were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have provided their consent for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}